Table 4.
Incidence of all-cause adverse effects after 6 months of follow-up
| Treatment | N | Total AE, n (%) | Retrograde ejaculation | Reduced ejaculate volume | Erectile dysfunction | Reduced libido | Hypotension |
|---|---|---|---|---|---|---|---|
| Monotherapy, n (%) | |||||||
| AB | 424 | 69 (16.3) | 31 (7.3) | 19 (4.5) | 3 (0.7) | 4 (0.9) | 10 (2.4) |
| 5ARI | 106 | 15 (14.2) | 0 | 2 (1.9) | 10 (9.4) | 9 (8.5) | 0 |
| HESr | 733 | 6 (0.8) | 0 | 0 | 0 | 0 | 0 |
| P. africanum | 34 | 1 (2.9) | 0 | 0 | 0 | 0 | 0 |
| Combination therapy, n (%) | |||||||
| AB + 5ARI | 105 | 32 (30.5) | 10 (9.5) | 8 (7.6) | 16 (15.2) | 16 (15.2) | 4 (3.8) |
| AB + HESr | 234 | 33 (14.1) | 12 (5.1) | 12 (5.1) | 7 (3.0) | 2 (0.9) | 6 (2.5) |
| 5ARI + HESr | 29 | 5 (17.2) | 0 | 1 (3.4) | 3 (10.3) | 3 (10.3) | 0 |
| Other combinations | 20 | 3 (15) | 0 | 1 (5.0) | 3 (15) | 1 (5.0) | 0 |
AE adverse effects, BP blood pressure, AB α- blockers, 5ARI 5α-reductase inhibitors, P. africanum Pygeum africanum, HESr hexanic extract of Serenoa repens